The LDN in HIVAIDS e-group is for those interested in use of low-dose naltrexone (LDN) in HIV+AIDS as carriers, those related to carriers, caretakers, health professionals or other helpers in the field. Autism as AIDS is a disorder of immune regulation; as an autism specialist, I found in an immune study in 2005 that LDN raised the CD4+ count in 16 weeks in the majority of autistic children and their parents. This and other information about LDN led me to take on coordination of a research study in Mali instigated several years ago by Dr. Bernard Bihari, the discoverer in 1985 of LDN’s beneficial effect in HIV+AIDS. The purpose of the clinical study is to investigate this drug’s effectiveness in preventing the progression of HIV+ status to full-blown AIDS. LDN will be compared to HAART drugs and a group using both is part of the study; no placebos are to be used in this project. I visited Mali with my husband Dr. Jack Zimmerman in December 2006 to meet the investigational team and inspect the laboratory facilities at the University of Bamako University Hospital where the study will take place. Jack is coordinating the social/cultural aspect of the study to help educate and use council groups for the participants on issues around HIV infectivity, gender imbalance being particularly important in the case of females who are increasingly and disproportionately being affected by the disease. Though we are still fund-raising, we are confident enough to go ahead and start the study; the 16 counselors started their council course on May 2-4, being taught by experienced trainers in council from South Africa. The IRB is being finalized soon, after which our research team will begin recruiting and evaluating the 250 participants for the study. We are planning to start the first group (20 will start each week until full) in mid-July. We are here to share and learn about LDN; welcome to all!! Jaquelyn McCandless M.D. and Jack Zimmerman, PhD